Clinical trial · Observational
Intraductal Papillary Mucinous Neoplasm With Malignant Change
Intraductal Papillary Mucinous Neoplasm (IPMN) With Malignant Change: Prospective Study to Assess Diagnostic Performance of CT and Magnetic Resonance Imaging (MR) According to International Consensus Guidelines 2012
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Because patient enrollment is so difficult.
Summary
Brief summary (as posted)
Purpose: To investigate diagnostic performance of CT and MR in intraductal papillary mucinous neoplasm with malignant change according to international consensus guidelines 2012. Hypothesis: According to 2012 consensus guidelines, enhanced solid component and main pancreatic duct size of larger than 10 mm will be significant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| IPMN | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Imaging predictor of malignant IPMN of the pancreas
- timeFrame
- one month
- description
- We will assess baseline CT and MRI findings of patients within one month after surgery.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who is suspected to have IPMN by imaging study or clinician * Time interval between imaging study and surgery less than 2 months Exclusion Criteria: * Patients who have pathology results not by surgery * Who is less than 20 years old * Who cannot voluntarily agree study design
References
Publications (0)
Data not yet available